NEPHROCARE HEALTH SERV L NEPHROPLUS NSEPHARMA
Company Overview
Nephrocare Health Services Limited operates a chain of kidney care clinics that provides dialysis healthcare services with dialysis centres in India, Uzbekistan, Nepal, Kingdom of Saudi Arabia, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. Nephrocare Health Services Limited was incorporated in 2009 and is based in Hyderabad, India.
Why Investors Should Care
Net profit has compounded at 250.6% per year over the last five years.
Revenue has grown at a 33.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.07.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹994.47 Cr (+32.9% YoY); net profit ₹76.84 Cr.
- Trailing 12 Months Year-on-year growth — revenue +32.9%, earnings +14.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 33.9%, profit CAGR 250.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 33.87% |
| 1 Year: | 32.89% |
Compounded Profit Growth
| 5 Years: | 250.60% |
| 1 Year: | 14.52% |
Stock Price Performance
| 1 Year: | +47.92% |
| 6 Months: | +26.21% |
| 3 Months: | -1.72% |
| 1 Month: | +0.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)53.15 · Neutral
P/E of 86.06 is above the sector median of 41.64 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 33.9% over 5 years.
- Profit CAGR of 250.6% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 86.1.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NEPHROPLUS NEPHROCARE HEALTH SERV L NSEPHARMA | 697.05 | 86.06 | ₹6,994.25 Cr | 0.00% | 13.27% | 6.88% | 33.87% | 250.60% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 197.26 Cr | 219.19 Cr | 246.00 Cr | 259.73 Cr | 265.62 Cr |
| Cost of Revenue | 87.40 Cr | 95.90 Cr | - | 109.19 Cr | 110.16 Cr |
| Gross Profit | 109.86 Cr | 123.29 Cr | - | 150.54 Cr | 155.46 Cr |
| Operating Expenses | 83.94 Cr | 91.36 Cr | 182.00 Cr | 111.53 Cr | 127.53 Cr |
| Operating Income | 25.92 Cr | 31.93 Cr | 41.00 Cr | 39.00 Cr | 27.92 Cr |
| EBITDA | 49.46 Cr | 55.41 Cr | 64.00 Cr | 64.18 Cr | 62.24 Cr |
| Interest Expense | 4.85 Cr | 6.12 Cr | 45.00 Cr | 5.96 Cr | 3.18 Cr |
| Pretax Income | 26.43 Cr | 29.92 Cr | -1.00 Cr | 36.36 Cr | 33.22 Cr |
| Tax Provision | 6.33 Cr | 5.05 Cr | -14.27 Cr | 4.12 Cr | 2.85 Cr |
| Net Income | 20.11 Cr | 24.87 Cr | -9.00 Cr | 32.24 Cr | 30.37 Cr |
| Diluted EPS | 2.00 | 2.48 | -5.24 | 3.35 | 2.96 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 286.00 Cr | - | 414.52 Cr | 539.55 Cr | 748.34 Cr | 994.47 Cr |
| Cost of Revenue | - | - | 221.41 Cr | 283.86 Cr | 352.24 Cr | 418.93 Cr |
| Gross Profit | - | - | 193.11 Cr | 255.69 Cr | 396.11 Cr | 575.53 Cr |
| Operating Expenses | 248.00 Cr | - | 189.47 Cr | 202.22 Cr | 297.12 Cr | 436.59 Cr |
| Operating Income | 3.00 Cr | - | 3.64 Cr | 53.47 Cr | 98.98 Cr | 138.95 Cr |
| EBITDA | 37.00 Cr | - | 52.87 Cr | 107.05 Cr | 178.77 Cr | 244.93 Cr |
| Interest Expense | 7.00 Cr | - | 14.59 Cr | 19.00 Cr | 18.87 Cr | 57.97 Cr |
| Pretax Income | 1.00 Cr | - | -8.59 Cr | 33.16 Cr | 87.44 Cr | 97.47 Cr |
| Tax Provision | 31.00 L | - | 3.20 Cr | -1.97 Cr | 20.34 Cr | 20.63 Cr |
| Net Income | 1.00 Cr | - | -11.79 Cr | 35.13 Cr | 67.10 Cr | 76.84 Cr |
| Diluted EPS | 3.40 | - | -1.17 | 3.50 | 6.69 | 8.10 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Total Assets | 428.00 Cr | - | 666.23 Cr | 806.02 Cr | 996.46 Cr | 1,470.87 Cr |
| Current Assets | - | - | 324.25 Cr | 390.03 Cr | 545.36 Cr | 839.17 Cr |
| Cash & Equivalents | - | - | 13.19 Cr | 61.15 Cr | 125.82 Cr | 123.89 Cr |
| Inventory | - | - | 26.27 Cr | 25.91 Cr | 26.62 Cr | 33.04 Cr |
| Receivables | - | - | 158.50 Cr | 202.67 Cr | 266.42 Cr | 316.89 Cr |
| Total Liabilities | - | - | 277.60 Cr | 392.31 Cr | 412.35 Cr | 354.37 Cr |
| Current Liabilities | - | - | 174.61 Cr | 242.59 Cr | 283.89 Cr | 299.41 Cr |
| Long Term Debt | - | - | 81.48 Cr | 123.24 Cr | 96.00 Cr | 4.70 L |
| Total Debt | 140.00 Cr | - | 213.73 Cr | 267.84 Cr | 257.78 Cr | 79.71 Cr |
| Total Equity | 247.00 Cr | - | 388.63 Cr | 413.71 Cr | 584.11 Cr | 1,116.49 Cr |
| Shares Outstanding | - | - | 10.03 Cr | 10.03 Cr | 10.03 Cr | 10.03 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 32.00 Cr | - | 11.27 Cr | 72.28 Cr | 135.35 Cr | 232.58 Cr |
| Investing Cash Flow | -62.00 Cr | - | -78.21 Cr | -50.66 Cr | -125.07 Cr | -410.44 Cr |
| Financing Cash Flow | 36.00 Cr | - | 59.97 Cr | 26.74 Cr | 54.37 Cr | 157.11 Cr |
| Capital Expenditure | -61.00 Cr | - | -73.74 Cr | -80.00 Cr | -100.80 Cr | -119.36 Cr |
| Free Cash Flow | -29.00 Cr | - | -62.47 Cr | -7.72 Cr | 34.55 Cr | 113.22 Cr |
| Net Change in Cash | 5.00 Cr | - | -6.97 Cr | 48.36 Cr | 64.64 Cr | -20.75 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 46.6% | 47.4% | 52.9% | 57.9% |
| Operating Margin % | 1.0% | - | 0.9% | 9.9% | 13.2% | 14.0% |
| Net Margin % | 0.3% | - | -2.8% | 6.5% | 9.0% | 7.7% |
| ROE % | 0.4% | - | -3.0% | 8.5% | 11.5% | 6.9% |
| ROCE % | - | - | 0.7% | 9.5% | 13.9% | 11.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NEPHROPLUS
NEPHROPLUS Stock Price and Chart — NSE:NEPHROPLUS - TradingView
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBBa3cxeXJOY1QtbVIxUWpRYjA5R1dzYVVPeDdVWXQycEQ5N1ZGOVNaajBxbjZKUUVXaU83M21WZ1hyQktiLTh6ajltT0tXOHNZbWxldzVNMWRKZ0lzYVBlcA?oc=5" target="_blank">NEPHROPLUS Stock Price and Chart — NS…
NephroPlus Reports 31.7% Revenue Growth in Q3FY26, Shares Investor Call Recording - scanx.trade
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQbkdYaGl4TVVQTm1uVGlGUzJuNm55MWNqQ0xyckdfdmZaM0F1eVIwTDFRQi1XZlEydm1QbzBKZmRyeW5HRWxnUU9uU3B4Z0paZ25Dd0c0UTdqS0cwV0sxSFV3ckFCakZZSGo2MEhEQ2tDUWFpYzhfTDMtX2RhdERhOUNZRG8zOF9rTHNrS0…
Nephrocare Health Services Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNVk0wa3N1blFsM3lCR1NCVlh1VE5PQklKdGFER1lWX0hKVG1fTTY1dTJja25MSmo3ekdOWDA0RGg3al9rY29UZC16ckdBcnYyRjhXTGZLcDZTUWNrNkdUVFZnRHdFSU5ReE5nMkxFTWxSX1NvdFBlc1luRGNtUGJ3YXM3WHpBcXhZcHVlaW…
NephroPlus off to strong FY27 start as overseas business drives growth: Nomura - Moneycontrol.com
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPck5zbl9Ia3RJakRkUlhWMzJWSDJ3QnVNeVZpR1hPSXhOY3hLSjBoV0xMRS1xNDlmbFVZalYtU1pwd0NuTGN2ZlNtVzdMQ2M1OUt1YXdaTzd1ZGtKXzctVVEwcDhISDU2aHc1NmI0ajQ2MHNOZmVxYUZOeFA2TmVNY2hFTVg1QUlfVk5Ian…
NEPHROPLUS Q2 2026 Earnings: Strong Revenue Surge of 32% YoY Drives Profitability and Investor Optimism - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNWHhtSHlaakhrMXI4TzBNZ2MzUDZRajZWNWFyUUVmU3cyOHhTaURpOFRzWXpEdWtxTHd1MDB5eHJLcVhNVGp2OVNFdTFuenN1T3I3TlI1VWd5ZDRxVWtCcWxXaHZLa256X3N3NE9iNi01TDV6Sm9PUVJUMFd5VzJaVDNMUG14dGVLUUVsYn…
NephroPlus sharpens global dialysis push as overseas business grows - Business Standard
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPTnJVb0pVWDl3dXppU05sM0FkNkJGWUpIN1p2NWZHS3ZVcko2WklZVnpQSUVkNUNOd2JFU1FHQlRKLUV3QmItOFJNM0NRWWRsdExBZ2VkS3VxX2Y1UGxsTldndjd2NEIzZGRIZ2NicnlVODVEWTJNVnpMUktkNTNub3lFbTg1UlY4VkRHMz…
NEPHROPLUS — Frequently Asked Questions
What is the current share price of NEPHROCARE HEALTH SERV L (NEPHROPLUS)?
As of 2026-09-08 04:53 IST, NEPHROCARE HEALTH SERV L (NEPHROPLUS) trades at ₹697.05 on NSE. Its 52-week range is ₹449.15 to ₹751.30.
What is the market capitalisation of NEPHROPLUS?
NEPHROCARE HEALTH SERV L (NEPHROPLUS) has a market capitalisation of ₹6,994.25 Cr on NSE.
What is the P/E ratio of NEPHROPLUS?
NEPHROPLUS trades at a trailing price-to-earnings (P/E) ratio of 86.06. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 6.24.
What is the return on equity (ROE) of NEPHROPLUS?
NEPHROPLUS has a return on equity (ROE) of 6.88%. Its return on capital employed (ROCE) is 13.27%.
Is NEPHROPLUS a good stock to buy?
This page provides a data-driven analysis of NEPHROCARE HEALTH SERV L (NEPHROPLUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.